HIMS vs MANE
HIMS: A consumer-first digital health platform connecting patients to licensed providers for prescription medications and wellness services across sexual health, weight loss, hair loss, and mental health via telehealth consultations. MANE: VeraDermics is a clinical-stage biotech developing an oral, extended-release minoxidil formulation (VDPHL01) to address the 80 million Americans with pattern hair loss who lack effective, convenient, non-hormonal treatment options.
Side-by-side fundamentals
| Metric | HIMS | MANE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $31.68 | $109.85 | |
| Market cap as of 2026-07-23 | $7.3B | $4.5B | |
| P/E as of 2026-07-23 | 57.12 | n/a | |
| Net margin as of 2026-07-23 | -0.6% | n/a | |
| Gross margin as of 2026-07-23 | +72.9% | n/a | |
| Operating margin as of 2026-07-23 | -1.3% | n/a | |
| ROE as of 2026-07-23 | -2.5% | -48.8% | HIMS higher |
| ROA as of 2026-07-23 | -0.6% | -45.9% | HIMS higher |
| Debt / equity as of 2026-07-23 | 2.18 | 0.00 | MANE lower |
| Revenue growth (YoY) as of 2026-07-23 | +32.8% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +64.5% | n/a | |
| Beta as of 2026-07-23 | 2.42 | -0.59 | |
| 1-year return as of 2026-07-22 close | -31.2% | +190.0% | MANE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.